Category Archives: Global News Feed

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

By Global News Feed

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.

Go here to see the original:
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

By Global News Feed

CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Excerpt from:
Relmada Therapeutics Announces Proposed Public Offering of Common Stock

OpGen Announces Results of Special Meeting of Stockholders

By Global News Feed

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Company’s Special Meeting of Stockholders held on December 8, 2021.

Read more from the original source:
OpGen Announces Results of Special Meeting of Stockholders

Certara to Host Investor Day on December 15, 2021

By Global News Feed

PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City. Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for 2022. There will also be a demonstration of the Simcyp™ Simulator.

See the rest here:
Certara to Host Investor Day on December 15, 2021

BrightInsight Named to the 2021 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups

By Global News Feed

For the Second Year in Row, CB Insights Recognizes BrightInsight for its Leading Global Platform for Biopharma and Medtech Regulated Digital Health Solutions For the Second Year in Row, CB Insights Recognizes BrightInsight for its Leading Global Platform for Biopharma and Medtech Regulated Digital Health Solutions

Original post:
BrightInsight Named to the 2021 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups

Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

By Global News Feed

SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Lymphoma Franchise Update” on Tuesday, December 14, 2021 at 8:00 AM ET.

More:
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

Chalice Brands Ltd. Announces Flagship Superstore and Relationship with Aventine Property Group

By Global News Feed

PORTLAND, Ore., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, is pleased to announce it has successfully completed an agreement (the “Agreement”) to lease a retail property located in Portland, Oregon from Aventine Property Group, Inc. (“Aventine”).

See more here:
Chalice Brands Ltd. Announces Flagship Superstore and Relationship with Aventine Property Group

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer…

By Global News Feed

GENEVA, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its autotaxin inhibitor IOA-289 and showing preclinical evidence of the role of autotaxin inhibition in breaking down tumor resistance mechanisms. IOA-289 will be the first autotaxin inhibitor to be clinically investigated in oncology. The data will be presented as a poster at the European Society of Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) taking place on December 8–11, 2021 as a virtual meeting.

Visit link:
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer...